Date: 2012-10-04
Type of information: R&D agreement
Compound:
Company: Cenix Biosciences (Germany) Ugichem (Austria)
Therapeutic area:
Type agreement: R&D
Action mechanism:
Disease:
Details: * On August 31, 2011, Cenix BioScience and ugichem GmbH, a gene silencing company with an innovative chemistry approach dedicated to expanding the current RNA therapeutics space, have entered into a research agreement to advance the latter\'s technology platform. Under the agreed work plan, Cenix will apply its long-standing expertise in combining gene silencing analyses with high content screening in cultured cells. Cenix will adapt and implement multi-parametric microscopy-based assays using the Definiens XD image analysis system, to facilitate characterization and optimization of ugichem\'s so-called Ugimer lead compounds.
Financial terms:
Latest news: * On October 4, 2012, Cenix BioScience and ugichem have announced an extension of the contract research project initiated in mid-2011. The present work will build on promising pharmacokinetic and functional data validating the unique therapeutic potential of Ugimers gleaned by ugichem from the first contract research project commissioned with Cenix, as well as from several parallel studies in recent months. Under the agreed new work plan, Cenix will continue to apply its long-standing expertise in combining gene silencing analyses with high content screening in cultured cells, to facilitate characterization and further optimization of ugichem’s lead compounds.
